Related Experiment Video
Updated: Apr 29, 2026

Refined Murine Model of Idiopathic Pulmonary Fibrosis
Published on: June 17, 2025
Microscopic polyangiitis associated with pulmonary fibrosis
Marcelo Fernandez Casares1, Alejandra Gonzalez, Mariano Fielli
1Department of Medicine, Pulmonary Section, Hospital Nacional A. Posadas, Illia s/n y Marconi, El Palomar, Buenos Aires, Argentina, mfercasar@intramed.net.ar.
Abstract:
Microscopic polyangiitis (MPA) is a systemic necrotizing vasculitis characterised by inflammation of the small blood vessels, the absence of granulommas on histopathological specimens, with few or no immune deposits and the presence of circulating anti-neutrophil cytoplasmic antibodies (ANCAs). The classic pulmonary manifestation is diffuse alveolar haemorrhage (DAH), but its association with pulmonary fibrosis (PF) has been increasingly reported and may be the first manifestation of MPA. Our aim was to evaluate MPA patients with PF and compare their characteristics and evolution to those of MPA patients without PF. We conducted a retrospective review of MPA patients followed in our hospital over a 15-year period. They were divided into two subgroups, with PF (MPA-PF) and without PF (MPA-non PF), and their clinical and functional features were compared. Nine of the 28 patients were classified as MPA-PF (32%). This subgroup showed significantly more respiratory symptoms and higher mortality than MPA-non PF subgroup. The most frequent chest computed tomographic pattern of PF was usual interstitial pneumonia. PF preceded other manifestations of vasculitis in five patients and occurred simultaneously in the remaining four. During the follow-up period, four deaths were reported in the MPA-PF subgroup. No deaths were registered in the MPA-non PF subgroup. We found a high prevalence of MPA-PF patients (32%), most of whom had a poor outcome and PF was often the first manifestation of the disease.
Insights
Microscopic polyangiitis (MPA) with pulmonary fibrosis (PF) affects 32% of patients and presents with more respiratory symptoms and higher mortality. Pulmonary fibrosis often appears before other MPA symptoms, indicating a poor prognosis.
Area of Science:
- Rheumatology
- Pulmonology
- Pathology
Background:
- Microscopic polyangiitis (MPA) is a small vessel vasculitis associated with anti-neutrophil cytoplasmic antibodies (ANCAs).
- Diffuse alveolar hemorrhage (DAH) is a known pulmonary manifestation, but pulmonary fibrosis (PF) is an increasingly recognized association.
- Pulmonary fibrosis may precede or coincide with other MPA manifestations.
Purpose of the Study:
- To evaluate MPA patients with pulmonary fibrosis (MPA-PF).
- To compare the characteristics and outcomes of MPA-PF patients with those without PF (MPA-non PF).
Main Methods:
- Retrospective review of MPA patients over 15 years.
- Classification into MPA-PF and MPA-non PF subgroups.
- Comparison of clinical and functional features between subgroups.
Main Results:
- 32% of MPA patients had pulmonary fibrosis (MPA-PF).
- The MPA-PF subgroup exhibited significantly more respiratory symptoms and higher mortality.
- Usual interstitial pneumonia was the most common CT pattern in MPA-PF.
- Pulmonary fibrosis preceded or occurred simultaneously with other vasculitis manifestations in all MPA-PF cases.
- Four deaths occurred in the MPA-PF subgroup versus none in the MPA-non PF subgroup.
Conclusions:
- Pulmonary fibrosis is a significant finding in a substantial proportion of MPA patients.
- MPA patients with PF face a poorer prognosis, characterized by increased respiratory symptoms and mortality.
- Pulmonary fibrosis can be an early or initial indicator of microscopic polyangiitis.
Related Concept Videos
Peripheral Artery Disease I: Introduction
Diabetic Nephropathy
Atypical Pneumonia
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
Chronic Obstructive Pulmonary Disease II: Emphysema
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...

